Comprehensive assessment of the safety of olodaterol 5？μg in the Respimat？ device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol

DOI: 10.1038/s41533-017-0059-1

Full-Text   Cite this paper   Add to My Lib

Abstract:

Demographic and baseline patient characteristics (treated population

Full-Text